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Résumé en
anglais
A role for glucose-dependent insulinotropic polypeptide (GIP) in controlling bone
resorption has been suspected. However uncertainty remains to identify whether GIP
act directly on osteoclasts. The aim of the present study were (i) to identify in different
osteoclast differentiation models (human peripheral blood mononuclear cells-PBMC,
murine bone marrow macrophage-BMM and murine Raw 264.7 cells) whether GIP was
capable of reducing osteoclast formation and resorption; (ii) ascertain whether the
highly potent GIP analogue N-AcGIP was capable of inducing a response at lower
concentrations and (iii) to decipher the molecular mechanisms responsible for such
effects. [d-Ala(2)]-GIP dose-dependently reduced osteoclast formation at concentration
as low as 1nM in human PBMC and 10nM in murine BMM cultures. Furthermore, [d-
Ala(2)]-GIP also reduced the extent of osteoclast resorption at concentration as low as
1nM in human PBMC and murine BMM cultures. The mechanism of action of [d-
Ala(2)]-GIP appeared to be mediated by reduction in intracellular calcium
concentration and oscillation that subsequently inhibited calcineurin activity and
NFATc1 nuclear translocation. The potency of the highly potent N-AcGIP was
determined and highlighted an effect on osteoclast formation and resorption at
concentration ten times lower than observed with [d-Ala(2)]-GIP in vitro. Furthermore,
N-AcGIP was also capable of reducing the number of osteoclast in ovariectomized mice
as well as the circulating level of type I collagen C-telopeptide. Pharmacological
concentrations required for reducing osteoclast formation and resorption provide the
impetus to design and exploit enzymatically stable GIP analogues for the treatment of
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